# Assessment of Safety and Efficacy of SGLT2is Among LN Patients

> **NCT06113900** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Ain Shams University** · enrollment: 50 (estimated)

## Conditions studied

- Lupus Nephritis

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab orally once daily

## Key facts

- **NCT ID:** NCT06113900
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-01-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06113900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06113900, "Assessment of Safety and Efficacy of SGLT2is Among LN Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06113900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*